A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope.
about
Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individualsSolution structure of the HIV gp120 C5 domainMatrix-assisted laser desorption ionization/mass spectrometry mapping of human immunodeficiency virus-gp120 epitopes recognized by a limited polyclonal antibody.Antigenic determinants synthesized in a library of randomly cloned fragments of the HIV-1 genome.Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers.Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins.Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.Induction of immunity to human immunodeficiency virus type-1 by vaccination.Comparison of the specificities of IgG, IgG-subclass, IgA and IgM reactivities in African and European HIV-infected individuals with an HIV-1 clade C proteome-based arraySerotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry.Heteroduplex mobility assay and phylogenetic analysis of V3 region sequences of human immunodeficiency virus type 1 isolates from Gulu, northern Uganda. The Italian-Ugandan Cooperation AIDS Program.A novel antibody-dependent cellular cytotoxicity epitope in gp120 is identified by two monoclonal antibodies isolated from a long-term survivor of human immunodeficiency virus type 1 infectionNative oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.B epitopes and selection pressures in feline immunodeficiency virus envelope glycoproteins.Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humansBiological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses.Detailed mapping of the antigenicity of the surface unit glycoprotein of equine infectious anemia virus by using synthetic peptide strategiesExpansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions.HIV-neutralizing antibodies: epitope identification and significance for future vaccine.Peptide component vaccine engineering: targeting the AIDS virus.Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins.Analysis of a highly immunodominant epitope in the human immunodeficiency virus type 1 transmembrane glycoprotein, gp41, defined by a human monoclonal antibodyBiological and molecular variability of human immunodeficiency virus type 2 isolates from The GambiaAnalysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1Localization of immunogenic domains in the human immunodeficiency virus type 2 envelopeSynthetic peptides define the fine specificity of the human immunodeficiency virus (HIV) gp160 humoral immune response in HIV type 1-infected chimpanzeesEffects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity.Immunology of HIV infection.Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies.Immunobiology of the HIV envelope.Variability and immunogenicity of caprine arthritis-encephalitis virus surface glycoproteinIdentification of a uniquely immunodominant, cross-reacting site in the human immunodeficiency virus endonuclease protein.Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis.Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies.A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design.Molecular mechanism of HIV-1 gp120 mutations that reduce CD4 binding affinity
P2860
Q24635002-347C8FC7-DD00-4179-AF20-AB0934833539Q27639717-CD4EA153-61F0-4B34-9C9A-A195D4DD3CE6Q32049913-20B159AA-4729-461E-AA96-D2A1D52DDBF8Q33252595-A7F3085E-5CFA-4BA4-BF2C-DFAE471F1DA6Q33560772-33698560-BCA1-42A1-AF2E-49BF92C88448Q34313555-C789F510-5252-4523-8F67-CBAF640B33FAQ34334135-4E887ED6-0CD2-497A-84D2-C650B88F4CB9Q34374835-39C212B3-0321-4591-9800-8BE37AC89D5BQ34540352-25C97160-3045-4379-99AB-73C4BADE9A62Q34540645-9F18B520-128E-4FC2-B985-48B9516745FDQ35057791-947353E0-466E-4A5E-A8D0-1BA24610FC0BQ35839973-4C9704C4-2D5D-4312-9596-38D089F62DA9Q35852493-1BE34489-2859-40F8-8AAC-50A5D941016FQ35876233-AD8C5D05-3D94-4E6E-93CD-84F655E3DF80Q36633402-756A8AD7-1CA2-4CBC-9914-3C2803C56940Q36640639-EC8C94A4-4991-4190-811C-F8B6B7D5C05AQ36641374-9A521546-BA96-4B67-8BCF-2263DACDE7B6Q36687749-1A6D096A-EB92-4BEB-B3C6-C493516635E1Q36690394-B6CBB54D-4637-4128-8A7C-572066F3FF19Q36707546-3411113A-5AA8-4A11-8462-802CCDF9DCD9Q36708990-D92C07E1-498A-4CBE-9660-8643E73553CBQ36708999-0CCF7132-323A-4DFC-AC6D-A7379303625FQ36781270-50B10AC4-ED97-445B-B61F-42FF191A05CEQ36782627-FC0D6E5C-9517-4B4E-B63C-59578E7B5A0DQ36784415-123579DB-C80E-48F1-951A-1803DCF24ED2Q36795889-44266D7F-3BC9-4918-8E78-E5B798942E9CQ36797905-03D9E86E-77C0-4F3C-88A3-AF8FD19C75D2Q36800188-1E40085B-F0EC-4865-9502-B24441464B19Q36872993-8A1FC5E6-0AF4-43DA-9C65-2DB9660C3483Q37546827-93B330A2-F6CC-4BC9-9496-82CE5308F373Q37615905-A71F0C3F-A657-4B99-A794-C0B6EBC5325DQ38046828-82DCF9EC-F3C3-4D44-8FFC-476274C50C5FQ38705312-3DA037F5-2593-43D8-8149-64D810B76668Q39591825-CB30A8A3-1FEF-426F-A8E7-B7325105F1B4Q40106499-596F7EAB-B9F2-4506-95D0-7CF352BB2C42Q40113553-BBFED2BE-5BD8-46E0-B177-7BCFEDA59785Q41573062-FB0353AA-F9C8-4C3A-94BA-5EB9E6B02990Q41819464-D3F0D8DD-171E-447A-85EE-FAAE0AB7439AQ57897038-2D60955B-2B34-42B4-9AF1-BCDBC2EF572B
P2860
A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope.
description
1987 nî lūn-bûn
@nan
1987 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1987 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
name
A conserved region at the COOH ...... ins an immunodominant epitope.
@ast
A conserved region at the COOH ...... ins an immunodominant epitope.
@en
A conserved region at the COOH ...... ins an immunodominant epitope.
@nl
type
label
A conserved region at the COOH ...... ins an immunodominant epitope.
@ast
A conserved region at the COOH ...... ins an immunodominant epitope.
@en
A conserved region at the COOH ...... ins an immunodominant epitope.
@nl
prefLabel
A conserved region at the COOH ...... ins an immunodominant epitope.
@ast
A conserved region at the COOH ...... ins an immunodominant epitope.
@en
A conserved region at the COOH ...... ins an immunodominant epitope.
@nl
P2093
P2860
P356
P1476
A conserved region at the COOH ...... ins an immunodominant epitope.
@en
P2093
A J Langlois
D P Bolognesi
G J Cianciolo
R R Randall
R Snyderman
T J Matthews
T J Palker
P2860
P304
P356
10.1073/PNAS.84.8.2479
P407
P577
1987-04-01T00:00:00Z